Clinical Trial Update: A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study of the investigational drug PF-01913539 in mild-to-moderate Alzheimer's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PF-01913539

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease, Dementia | Phase 2 | Status: WITHDRAWN